Research ArticleOriginal Article

Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210

Xuelian Chen, Lanying Ma, Xi Wang, Hongnan Mo, Dawei Wu, Bo Lan, Dong Qu, Hongtu Zhang, Jing Huang and Binghe Xu
Cancer Biology & Medicine February 2019, 16 (1) 173-181; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0172

Article Figures & Data

Figures

  • 1
    1

    Spontaneous regression of RCHs for an esophageal squamous cell carcinoma patient (male, 51 years old) during treatment with SHR-1210. (A) Four weeks after initiation of SHR-1210. (B) Ten weeks after initiation of SHR-1210. (C) Sixteen weeks after initiation of SHR-1210.

  • 2
    2

    Spontaneous regression of RCHs for a triple negative breast cancer patient (female, 50 years old) after termination of SHR-1210. (A) Four weeks after initiation of SHR-1210. (B) Eight weeks after initiation of SHR-1210 (the end of treatment). (C) Eight weeks after the termination of SHR-1210.

  • 3
    3

    A dome-shaped, red nodule on the chest. (A) Histopathology of the resected specimen showed a well-circumscribed proliferation of small capillaries (H&E staining, B, 4 ×; C, 100 ×; D, 400 ×)

Tables

  • 1

    Baseline characteristics of treated patients

    CharacteristicsDose cohortAll patients
    (n = 98)
    60 mg (n = 12) 200 mg (n = 74) 400 mg (n = 12)
    Median age, years52 (35–66)59 (29–75)57.5(35–65)59 (29–75)
    Gender, n (%)
     Male8 (66.7)61 (82.4)10 (83.3)79 (80.6)
     Female4 (33.3)13 (17.6)2 (16.7)19 (19.4)
    ECOG performance status, n (%)
     010(83.3)60(81.1)10 (83.3)81(82.7)
     12(16.7)14(18.9)2(16.7)17(17.3)
    Tumor types
     Esophageal squamous cell carcinoma337242
     Small cell carcinoma of esophagus0101
     Triple negative breast cancer2417
     Adenocarcinoma of the esophagogastric junction and stomach325230
     Lung adenocarcinoma2013
     Nasopharyngeal squamous cell carcinoma2013
     Hepatocellular carcinoma0325
     Intrahepatic cholangiocarcinoma0101
     Colorectal adenocarcinoma0224
     Cervical squamous cell carcinoma0101
     Bladder transitional cell carcinoma0011
    Previous systemic therapies n (%)
     ≤ 10 (0)23 (31.1)2 (16.7)25 (25.5)
     25 (41.7)26 (35.1)4 (33.3)35 (35.7)
     27 (58.3)25 (33.8)6 (50.0)38 (38.8)

    ECOG, Eastern Cooperative Oncology Group.

    • 2

      Clinical features of reactive capillary hemangiomas (RCHs)

      FeaturesDose cohortAll patients
      (n=98)
      60 mg (n=12) 200 mg (n=74) 400 mg (n=12)
      RCH events n (%) 8 (66.7)64 (86.5)12 (100)84 (85.7)
      Time to onset, median (range), days53.5 (43–114)18.5 (2–144)10 (3–32)19.5 (2–144)
      No. of injections before onset, median (range)3.5 (3–8)1(1–9)1 (1)1 (1–9)
      Peak time, median (range), days115 (71–169)84 (28–171)84 (70–98)84 (28–71)
      No. of injections to peak time median (range)7 (4–12)5.5 (2–11)5 (4–6)5 (2–12)
      Severity
       Grade 1854971
       Grade 2010313
       Grade 3–40000
      Location
       Cutaneous only856872
       Mucosal only0000
       Mixed (cutaneous and mucosal)08412
    • S1

      Tumor response in different types of cancer

      Tumor typesNo.(n = 98) Tumor response
      CR+PRSDPD
      Esophageal squamous cell carcinoma*42111117
      Small cell carcinoma of esophagus1001
      Triple negative breast cancer7007
      Adenocarcinoma of the esophagogastric junction and stomach307617
      Lung adenocarcinoma3102
      Nasopharyngeal squamous cell carcinoma3102
      Hepatocellular carcinoma5122
      Intrahepatic cholangiocarcinoma1100
      Colorectal adenocarcinoma4121
      Cervical squamous cell carcinoma1001
      Bladder transitional cell carcinoma1100

      * Tumor response of the three patients was not available. CR: complete remission; PR: partial remission; SD: stable disease; PD: progression disease.

      Back to top

      In this issue

      Print
      Download PDF
      Email Article
      Citation Tools

      Jump to section

      Keywords